Barclays
BCAX

Barclays’s Bicara Therapeutics BCAX Stock Holding History

Barclays’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
34,698
+5,875
+20% +$131K ﹤0.01% 2774
2026
Q1 		$573K Sell
28,823
-74,418
-72% -$1.28M ﹤0.01% 3109
2025
Q4 		$1.74M Buy
103,241
+55,093
+114% +$941K ﹤0.01% 3041
2025
Q3 		$760K Sell
48,148
-9,186
-16% -$103K ﹤0.01% 3534
2025
Q2 		$533K Buy
57,334
+37,063
+183% +$442K ﹤0.01% 3726
2025
Q1 		$264K Sell
20,271
-9,836
-33% -$131K ﹤0.01% 3897
2024
Q4 		$524K Buy
30,107
+20,107
+201% +$418K ﹤0.01% 3795
2024
Q3 		$255K Buy
+10,000
New +$255K ﹤0.01% 4175

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's BCAX Position: Q2 2026 in Review

Barclays increased its Bicara Therapeutics (BCAX) stake by 20% in Q2 2026, buying an estimated $131K and bringing the position to 34,698 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2774.

Barclays first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.74M in Q4 2025. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Barclays held 34,698 shares of Bicara Therapeutics worth $1.03M as of Q2 2026.
  • Barclays bought 5,875 Bicara Therapeutics shares in Q2 2026, an estimated $131K.
  • Bicara Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2774 holding.
  • Barclays first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Barclays's Bicara Therapeutics position peaked at $1.74M in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.